ACADIA Pharmaceuticals, Inc. (NASDAQ:ACAD)
| CAPS Rating |
|
|---|---|
| Open | $1.78 |
| Previous Close | $1.81 |
| Daily Range | $1.77 - $1.81 |
| 52-Week Range | $0.90 - $3.30 |
| Market Cap | $95.04M |
| P/E Ratio | 2.40 |
| Dividend (Yield) | N/A (N/A) |
| Volume | 429,219 |
| Average Daily Volume | 0 |
How do you think ACAD will perform against the market?
Caps
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
ACAD Advanced Details
- CAPS Community Analysis: Commentary, Scorecard
- Advanced Financial Analysis: Historical Prices, Chart, Stats, Ratios, Earnings/Growth Rates, Statements, SEC Filings
ACAD News and Commentary
- Zacks #1 Rank Additions for Wednesday - Tale of the Tape – NASDAQ
- Zacks #1 Rank Additions for Monday - Tale of the Tape – NASDAQ
- Zacks #1 Rank Additions for Thursday - Tale of the Tape – NASDAQ
- Zacks #1 Rank Additions for Tuesday - Tale of the Tape – NASDAQ
- Zacks #1 Rank Additions for Friday - Tale of the Tape – NASDAQ
- US Stock Futures: HOT STOCKS TO WATCH – SmartMoney
- 11 Hot Trades (Charts ) for 7/6 – Blog at The Motley Fool
- 7 Biotech Penny Stocks to Buy – NASDAQ
- Acadia Pharmaceuticals: Investing With No Safety Net – Minyanville
- Acadia Pharmaceuticals - Investing With No Safety Net – Blog at The Motley Fool
- Acadia Pharmaceuticals - Investing With No Safety Net – Blog at The Motley Fool
- Dream Stocks: April's Strongest Performers – Minyanville
- Optimistic on Acadia: Solid Cash Position, Increased Confidence in Phase 3 Trial – SeekingAlpha
- Allergan Gets Subpoenas On Acadia Affiliation, Eye Ventures – SmartMoney
- Biotech Merger/Acquisition Activity Mixed During Major Conference – SeekingAlpha
- Are These Stocks (Plus One ETF) Overbought and Poised to Fall? – SeekingAlpha
- Is BioSante Pharmaceuticals Next in Line to Receive Institutional Praise? – SeekingAlpha
- UPDATE 1-Acadia, Biovail plan more study on Parkinson's drug – Reuters
- 10 Stocks Shaking the Market – The Motley Fool
- What are some pharmaceutical stocks that will be reviewed by the FDA soon? – Blog at The Motley Fool

RSS Headlines
Fool UK